176 related articles for article (PubMed ID: 9769840)
1. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
[TBL] [Abstract][Full Text] [Related]
2. Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
Everaert H; Vanhove C; Lahoutte T; Muylle K; Caveliers V; Bossuyt A; Franken PR
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1615-9. PubMed ID: 14504831
[TBL] [Abstract][Full Text] [Related]
3. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
[TBL] [Abstract][Full Text] [Related]
4. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
5. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.
Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
J Nucl Med; 1998 Dec; 39(12):2145-52. PubMed ID: 9867159
[TBL] [Abstract][Full Text] [Related]
7. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
8. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.
Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
Radiology; 1998 Mar; 206(3):749-54. PubMed ID: 9494496
[TBL] [Abstract][Full Text] [Related]
9. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
10. [Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes].
Schirrmeister H; Kotzerke J; Rentschler M; Träger H; Fenchel S; Nüssle K; Diederichs CG; Reske SN
Rofo; 1998 Sep; 169(3):310-4. PubMed ID: 9779073
[TBL] [Abstract][Full Text] [Related]
11. [A search for the focus in patients with fever of unknown origin: is positron-emission tomography with F-18-fluorodeoxyglucose helpful?].
Lorenzen J; Buchert R; Bleckmann C; Münchow N; Bohuslavizki KH
Rofo; 1999 Jul; 171(1):49-53. PubMed ID: 10464505
[TBL] [Abstract][Full Text] [Related]
12. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Delbeke D; Martin WH; Patton JA; Sandler MP
Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
[TBL] [Abstract][Full Text] [Related]
13. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
14. Chronic thyroiditis: diffuse uptake of FDG at PET.
Yasuda S; Shohtsu A; Ide M; Takagi S; Takahashi W; Suzuki Y; Horiuchi M
Radiology; 1998 Jun; 207(3):775-8. PubMed ID: 9609903
[TBL] [Abstract][Full Text] [Related]
15. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.
Shreve PD; Steventon RS; Deters EC; Kison PV; Gross MD; Wahl RL
Radiology; 1998 May; 207(2):431-7. PubMed ID: 9577492
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of a short acquisition protocol for whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose.
Paul AK; Tatsumi M; Fujino K; Hashikawa K; Nishimura T
Eur J Nucl Med; 2001 Nov; 28(11):1697-701. PubMed ID: 11702113
[TBL] [Abstract][Full Text] [Related]
17. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
[TBL] [Abstract][Full Text] [Related]
18. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
19. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
20. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
